key: cord-0752716-tssioos7 authors: Natori, Yoichiro; Anjan, Shweta; Martin, Eric F; Selvagi, Gennaro; Villavicencio, Aasith; Coro, Ana; Mendez‐Castaner, Lumen A.; Mattiazzi, Adela; Pagan, Javier; Ortigosa‐Goggins, Mariella; Roth, David; Kupin, Warren; O’Brien, Christopher B.; Arosemena, Leopoldo R.; Ciancio, Gaetano; Burke, George W.; Morsi, Mahmoud; Figueiro, Jose M.; Chen, Linda; Tekin, Akin; Miyashiro, Rafael; Simkins, Jacques; Abbo, Lilian M.; Vianna, Rodrigo M.; Guerra, Giselle title: When is it Safe to perform Abdominal Transplantation in patients with prior SARS‐CoV‐2 infection: A Case Series date: 2021-05-25 journal: Clin Transplant DOI: 10.1111/ctr.14370 sha: a447a5f551c789623f3dfeb7ad475a2be3365951 doc_id: 752716 cord_uid: tssioos7 BACKGROUND: The Coronavirus disease 2019(COVID‐19) pandemic has negatively impacted worldwide organ transplantation. However, there is limited information on recipients transplanted after SARS‐CoV‐2 infection. A full understanding of this scenario is required, as transplantation is a lifesaving procedure and COVID‐19 remains an ongoing threat. METHODS: Abdominal organ transplant recipients diagnosed with COVID‐19 prior to transplantation were identified by chart review and clinical data was collected. The primary outcome was the transplant outcome including graft loss, rejection and death, and reactivation of infection posttransplant. RESULTS: We identified 14 patients who received abdominal organ transplants after symptomatic PCR confirmed SARS‐CoV‐2 infection; four patients had a positive PCR at the time of admission for transplantation. The median time of follow‐up was 79 (22‐190) days. One recipient with negative PCR before transplant tested positive 9 days after transplant. One of 14 transplanted patients developed disseminated mold infection and died 86 days after transplant. During follow‐up, only one patient developed rejection; thirteen patients had favorable graft outcomes. CONCLUSIONS: We were able to perform abdominal transplantation for patients with COVID‐19 before transplant, even with positive PCR at the time of transplant. Larger studies are needed to determine the time to safe transplant after SARS‐CoV‐2 infection. The Coronavirus disease 2019 (COVID- 19) pandemic has burdened health care systems world-wide and negatively impacted organ donation and transplantation 1 . A significant decrease in the number of transplants and an increased waitlist mortality were initially reported from US transplant regions. However, deceased donor transplant activity is now coming back at or above pre-pandemic levels. 2 There is a large volume of data regarding managing post solid organ transplant (SOT) recipients with COVID-19 3 , but it is still uncertain when patients with a previous history of COVID-19 can proceed with transplantation, especially since 20% of the US population has been exposed to the virus. 4 When conducting transplants, we need to assess the risks versus benefits of each transplant case, especially with regards to specific organ types. After induction, T-cell and B-cell mediated immunity is reduced, which may result in relapse of SARS-CoV-2 infection, even though there is no conclusive evidence of the latter. COVID-19 is also associated with secondary infections, such as invasive pulmonary aspergillosis, which can increase mortality post-transplant. To undergo a safe transplant, preventive measures must be taken. 5, 6 On the other hand, there is a significant benefit from SOT that improves quality of life and is also a life-saving procedure. There is also evidence of an increase in mortality in pre-kidney transplant recipients on the transplant waitlist 7, 8 amidst a pandemic; thus, transplantation is still the best therapeutic option for end organ failure. Although a limited number of lung transplantations were performed for the recipients who developed COVID-19 while SARS-CoV-2 polymerase chain reaction (PCR) positivity 9, 10 , only a few were reported for abdominal transplant for patients with a previous history of COVID-19 infection [11] [12] [13] [14] . This article is protected by copyright. All rights reserved To provide some guidance on the safety of procedures and promptness to abdominal transplant after infection, we present our pilot experience for patients with a history of COVID-19, who subsequently received liver and/or kidney transplants. This article is protected by copyright. All rights reserved This was a single center retrospective cohort study conducted at the Miami Transplant Institute, Jackson Health System, Miami, Florida, USA. We included all patients diagnosed with SARS-CoV-2 infection before abdominal transplant between March and December 2020. We excluded patients who showed antibody positivity without having documented PCR positive test result. Our center implemented a strict protocol to test all recipients with nasopharyngeal (NP) swab PCR on the day of admission for transplant since April 10, 2020, along with antibody testing for SARS-CoV-2. All documented Cycle threshold (Ct) value was analyzed via Cepheid platform. Antibody testing targeting spike protein was performed via ortho diagnostics platform to measure IgG and total antibodies, expressed in signal/cutoff ratio (s/co) (lower limit of positivity: 1.0). All potential transplant recipients who had a history of COVID-19 were assessed for transplant candidacy in the institutional committee. For non-urgent transplants, based on the infectivity studies 15, 16 , we used 35 as a threshold to proceed to transplant. For urgent liver transplants, we used a lower threshold, which was 25, to get listed. However, final decision to proceed with transplantation was made on a case-by-case basis as determined by the severity of the disease, the duration from the diagnosis, radiological findings, and symptoms. During transplant surgery, for PCR positive recipients, we implemented active SARS-CoV-2 infection precaution methods including wearing N95 masks and using negative pressure surgery rooms. After the transplantation, for the surveillance purposes, we repeated PCR testing. This study was approved by the University of Miami research ethics board This article is protected by copyright. All rights reserved During the study period, we tested patients for COVID-19 within 12 hours prior to transplant. The median time of follow-up and graft survival was 79 (22 -190) days. Four patients had positive NP swab PCR 12 hours prior to transplant. One patient with a negative PCR developed a reactive PCR in the immediate post-transplant period. In addition to that, 9 patients who showed negative NP swab PCR yet showed positive antibody testing with a previous history of PCR positivity (Table 1) . We A 37-year-old female, with a history of overlap syndrome including autoimmune hepatitis and primary biliary cholangitis being treated with mycophenolate and prednisone, was diagnosed with COVID-19 90 days prior to liver transplantation. Clinical symptoms of infection included fever, cough and shortness of breath that progressed to pneumonia and was treated with hydroxychloroquine. Respiratory symptoms continued for one week and after that, she was asymptomatic. Repeated PCR 33 days after diagnosis was negative. At the time of admission for a liver transplant, repeat NP swab PCR was positive, with a Ct value of 35. We also confirmed IgG (24.8 s/co) and total immunoglobulin positivity (88.1 s/co). High-dose methylprednisolone was used for induction immunosuppression. Five days after transplant, NP swab PCR was negative. Follow-up at 190 days revealed stable allograft function, no signs of infections nor surgical complications. This article is protected by copyright. All rights reserved A 55-year-old male with acute alcoholic hepatitis was transferred to our center for transplant evaluation. NP swab PCR at the time of admission was negative. Six days after admission, after known nosocomial exposure, a repeated SARS-CoV-2 PCR became positive. Six days after diagnosis, he was febrile and hypoxic with bilateral opacities in chest X ray. He received dexamethasone, remdesivir, convalescent plasma along with empiric antibiotics. Unfortunately, he also developed kidney failure secondary to acute tubular necrosis. Thirty-five days after diagnosis, this patient was asymptomatic from COVID-19 and was actively listed for a simultaneous liver-kidney transplant. Transplantation took place 53 days after diagnosis; and at that time, PCR still resulted positive with a Ct value of 25 with positive antibody testing (IgG 10.9 s/co, Total 85.5 s/co). The post-transplant course was complicated by infected hematoma as well as septic thrombophlebitis from a peripherally inserted central catheter. Eventually, this patient developed severe disseminated mold infection. Pathology from the skin and amputated foot tissue showed non septated hyphae with greater than 90 degrees angles branches, but culture showed negative. This patient died 86 days after the transplant. A 63-year-old male, with end stage renal disease secondary to type one diabetes, contracted SARS-CoV-2 infection 64 days prior to kidney transplant. He was symptomatic with fever and shortness of breath but never required hospitalization. Twenty-four days after diagnosis, NP swab PCR was reported negative. At the time of transplant, we repeated SARS-CoV-2 PCR testing to be positive with Ct value of 32.5. Also, the COVID-19 IgG of 30.9 s/co ratio and total antibody was 392 This article is protected by copyright. All rights reserved s/co. Kidney transplant was conducted, and thymoglobulin 3mg/kg total dose, along with basiliximab and high dose steroids were given as induction immunosuppression. No reduction in induction or maintenance regimens took place. Repeated NP swab was positive 4 days after transplant with Ct value of 41 and achieved negativity at post-operative day 11. As a follow-up on day 129, the patient remained asymptomatic and graft function normal. A 66-year-old male, with end stage renal disease from hypertension, contracted SARS-CoV-2 infection 60 days prior to his kidney transplant. His symptoms included fever and cough, which This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved To further complicate the situation, prolonged PCR positivity has been well documented, especially in immunocompromised patients. 20 Some reports showed prolonged viral culture positivity in immunocompromised hosts. Viral culture would be a more accurate test; however, viral culture requires extensive resources, including a biosafety level 3 microbiology laboratory. To date, PCR is recognized as the gold standard, and even if PCR is negative, no established rule exists to precisely determine the safe period of time to proceed with transplantation because of concern for relapse due to immunosuppression. We decided to use the PCR Ct value to determine the timing for the transplant. Ct value has been reported as a more validated indirect measure of infectivity compared to others 9, 16, 21 but not established to assess the degree of disease severity or potential for recurrence after immunosuppression. At this time, in patients with resolution of clinical infection and high Ct values, there is no supporting data that predicts disease relapse after induction immunosuppression therapy for transplantation. In our health system, and the state of Florida, routine viral cultures for SARS-CoV2 are not available. We used Ct values as a surrogate marker of culture negativity to determine the timing for abdominal transplant for pre-transplant recipients whose PCR was still positive. Of note, two patients who had a poor outcome showed PCR positivity at the time or soon after transplant, which was lower than the other two patients who did well after transplant. In addition to Ct values, we measured antibody titers to ensure the potential recipients have mounted a significant immune response against SARS-CoV-2 prior to transplant. For PCR negative patients, positive antibody was not a requirement to get listed for transplant at our institute. This article is protected by copyright. All rights reserved It is important to note that this study has several limitations. First, this is a single center analysis with limited number of cases. Second, the background of the potential recipients, treatment methods including immunosuppression protocols and surgical procedures, are different among SOT centers. We only had 14 patients and thus the power is too small to validate any significant conclusions; yet as a case series some trends may be inferred. Also, the use of Ct values to guide clinical decision-making may contain some problems as there are several factors related to the patient, specimen, and specific PCR assay that can result in significant inter-and intra-patient variability in Ct values. In addition to this, given that the patients were all at least 53 days from the initial diagnosis, it might be unlikely that any had an actual active viral infection that would become more apparent post-transplant. Lastly, the follow-up period was short so long-term outcomes including the incidence of rejection, graft loss, or other late-onset opportunistic infections are not available; yet, we believe we had enough follow-up period to monitor for recurrence of SARS-CoV-2. In conclusion, we were able to perform abdominal transplantation for patients who developed COVID-19 prior to transplant, even with positive PCR at the time of transplant. To validate this model, we will need a larger sample size study and longer follow-up. This article is protected by copyright. All rights reserved Organ procurement and transplantation during the COVID-19 pandemic Early Impact of COVID-19 on Solid Organ Transplantation in the United States COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature 4. (CRC) JHCRC. COVID-19 United States Cases by County Inpatient COVID-19 Outcomes in Solid Organ Transplant Recipients Compared to Non-Solid Organ Transplant Patients: A Retrospective Cohort Is the outcome of SARS-CoV-2 infection in solid organ transplant recipients really similar to that of the general population? SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study Outcomes of Renal Transplant Recipients With SARS-CoV-2 Infection in the Eye of the Storm: A Comparative Study With Waitlisted Patients Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient Lung transplantation for patients with severe COVID-19 Successful simultaneous pancreas and kidney transplant in a patient post-COVID-19 infection Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose Liver transplantation in COVID-19 positive patients Accepted Article This article is protected by copyright. All rights reserved 14 Early Liver transplantation after COVID-19 To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value Predicting infectious SARS-CoV-2 from diagnostic samples Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer Shedding from an Asymptomatic Immunocompromised Individual with Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study COVID-19 in lung transplant patients: A case series Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates